MedTrace Logo

Add on Lacosamide Versus High Dose Monotherapy

NCT01345058 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2026-04-14

Study results available
· View outcomes & findings →

Summary

This is a study to determine whether a combination of low dose lacosamide and levetiracetam is more effective than high dose levetiracetam in patients who have failed low dose levetiracetam.

Conditions

Interventions

DRUG

lacosamide

Lacosamide maximum of 200 mg/day, to be titrated as follows: * Week 1: 50 mg twice a day * Beginning Week 2: 100 mg twice a day.

DRUG

levetiracetam

Low dose ≤1500 mg/day, High dose \>1500 mg/day

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Jong Woo Lee, MD, PhD · Brigham and Women's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-01
Primary Completion
2014-02-15
Completion
2014-10-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01345058 on ClinicalTrials.gov